An Exciting Breakthrough in Stomach Cancer Treatment
An innovative new treatment for tackling some of the toughest stomach cancers has shown remarkable promise in a phase 2 clinical trial, leading to significant improvements in tumor shrinkage and survival rates.
The treatment involves a form of CAR T cell immunotherapy, where the body’s own immune cells are extracted, trained to target cancer cells more effectively, and then reintroduced into the bloodstream.
Known as satricabtagene autoleucel, or satri-cel, this therapy targets the CLDN18.2 protein that certain tumors utilize for growth. Patients who received satri-cel in the trial lived approximately 40 percent longer on average.
Researchers from various institutions across China conducted the trial, which involved 156 participants with gastric or gastroesophageal junction cancer that had not responded to at least two previous treatments. These patients were essentially running out of options before participating in the trial.
In the satri-cel group, patients had a median average survival of 7.92 months compared to 5.49 months in the control group. Notably, 22 percent of satri-cel patients experienced significant tumor shrinkage, in contrast to just 4 percent of control patients.
The median time before cancer progression was 3.25 months with satri-cel and 1.77 months without, showcasing the treatment’s efficacy across various metrics.
“This brings new hope to patients with otherwise medically untreatable conditions,” remarked oncologist Lin Shen from Beijing Cancer Hospital.
While satri-cel treatment led to significant side effects, including a drop in blood cell counts, researchers believe these side effects are manageable.
CAR T cell therapy has already demonstrated effectiveness in treating blood cancers, and promising results are emerging for solid tumors such as brain cancer and pancreatic cancer. The success seen in treating stomach cancers adds to this growing list of achievements in cancer research.
While this treatment is not a cure, it represents a significant advancement in managing cancer tumors by enhancing the body’s immune response against malignant growths.
“We are further exploring satri-cel’s potential in adjuvant settings and as first-line sequential therapies, aiming to intervene earlier in the disease course, extend patients’ survival, and ultimately pursue potential cures,” Shen added.
The research findings have been published in The Lancet.
